EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
164 hedge funds and large institutions have $633M invested in Eagle Pharmaceuticals, Inc. in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 55 increasing their positions, 68 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
164
Holders Change
-4
Holders Change %
-2.38%
% of All Funds
3.37%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
18
Increased
55
Reduced
68
Closed
22
Calls
$983K
Puts
$388K
Net Calls
+$595K
Net Calls Change
+$3.39M
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$13.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$9.02M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$7.29M |
| 5 |
Millennium Management
New York
|
+$5.09M |
Top Sellers
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$11.4M |
| 2 |
Goldman Sachs
New York
|
-$9.88M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$7.28M |
| 4 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$6.88M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$5.76M |
